Literature DB >> 11249650

Structural implications for the design of molecular vaccines.

V Apostolopoulos1, M Yu, I F McKenzie, I A Wilson.   

Abstract

The major histocompatibility complex molecules bind and present short antigenic peptide fragments on the surface of antigen presenting cells to T-cell receptors. Recognition of peptide-MHC by cytotoxic T-cells initiates a cascade of signals to T-cells, which in turn destroy the antigen presenting cell. In the design of molecular vaccines for the treatment of diseases, an understanding of the 3-dimensional structure of MHC class I and is interaction with both peptide and T-cell receptor is an important prerequisite. In this review, we will discuss such crystal structures, as well as structures of glycopeptides and alternative T-cell antigens presented by MHC molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11249650

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  3 in total

1.  Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.

Authors:  Eliada Lazoura; Jodie Lodding; William Farrugia; Paul A Ramsland; James Stevens; Ian A Wilson; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

2.  Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.

Authors:  Milos Aleksic; Omer Dushek; Hao Zhang; Eugene Shenderov; Ji-Li Chen; Vincenzo Cerundolo; Daniel Coombs; P Anton van der Merwe
Journal:  Immunity       Date:  2010-02-04       Impact factor: 31.745

3.  Structural and kinetic basis for heightened immunogenicity of T cell vaccines.

Authors:  Ji-Li Chen; Guillaume Stewart-Jones; Giovanna Bossi; Nikolai M Lissin; Linda Wooldridge; Ed Man Lik Choi; Gerhard Held; P Rod Dunbar; Robert M Esnouf; Malkit Sami; Jonathan M Boulter; Pierre Rizkallah; Christoph Renner; Andrew Sewell; P Anton van der Merwe; Bent K Jakobsen; Gillian Griffiths; E Yvonne Jones; Vincenzo Cerundolo
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.